PIILLNCT04073797
PET Imaging of Inflammation and Lipid Lowering Study
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 8 versions: 7 with changes below, 1 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Primary completion date changed from estimate of Oct 1, 2025 to May 30, 2026 Show 6 more changesShow less
- Eligibility criteria expanded, about 20 words
- Trial status changed: Unknown → Completed
- Enrollment target: estimated 63 to confirmed 60
- Site details revised
- Collaborators: 4 to 5
- Publications: details revised at 2 of 2 entries
- Minor Changed Registry marked status Unknown; last known: Recruiting
- Notable Primary completion date: Mar 1, 2025 to Oct 1, 2025
- Trial status: Recruiting to Unknown
- Study completion date: Mar 1, 2025 to Mar 1, 2026
Notable Trial status: Not Yet Recruiting to Recruitingv6 Show 5 more changesShow less
- Primary endpoints: 1 to 2
- Start date changed from estimate of Mar 1, 2023 to Mar 20, 2023
- Study description expanded, about 64 words
- Site details revised
- Collaborators: 2 to 4
Notable Primary and study completion dates pushed to Mar 1, 2025v5 Show 9 more changesShow less
- Start date: Aug 20, 2021 to Mar 1, 2023
- Eligibility criteria expanded, about 63 words
- Trial status: Recruiting to Not Yet Recruiting
- Enrollment target: 56 to 63
- Interventions: 68Ga-DOTATATE PET-MRI (Diagnostic Test), PCSK9 inhibitor (Drug) to 68Ga-DOTATATE PET-MRI (Diagnostic Test), Colchicine (Drug), Inclisiran (Drug)
- Secondary endpoints revised (3)
- Study description expanded, about 13 words
- Site details revised
- Study arms: 4 to 3
Show 2 earlier versionsHide 2 earlier versions
Notable Trial status: Not Yet Recruiting to Recruitingv4 Show 4 more changesShow less
- Primary completion date: Oct 1, 2023 to Mar 1, 2023
- Study completion date: Oct 1, 2023 to Mar 1, 2024
- Start date changed from estimate of Jul 1, 2021 to Aug 20, 2021
- Site details revised
- Notable Start date: Oct 1, 2019 to Jul 1, 2021v3
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Carotid 68Ga-DOTATATE PET
Timeframe: 12 weeks
Carotid UPSA imaging
Timeframe: 12 weeks
Secondary (3)
MRI plaque burden
Carotid 68Ga-DOTATATE vs. serum lipids
Carotid 68Ga-DOTATATE vs. hsCRP
Arms and interventions
Stable CVD - treatmentExperimental
Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to add on therapy with inclisiran + placebo tablet
Stable CVD - placebo controlActive comparator
Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + colchicine tablet
HeFH - treatmentPlacebo comparator
Stable CVD with LDL ≥2.6 despite maximally tolerated statins ± other lipid lowering therapies, randomised to placebo injection + placebo tablet
Drugs: Inclisiran, Colchicine
Diagnostic tests: 68Ga-DOTATATE PET-MRI
Sites
1 site in 1 country
- University of CambridgeCambridge, United Kingdom